固定剂量复方胶囊中利福平、异烟肼和吡嗪酰胺的生物利用度。
Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
作者信息
Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H
机构信息
National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
出版信息
Int J Tuberc Lung Dis. 1998 Oct;2(10):824-30.
SETTING
The absorption of rifampicin, isoniazid and pyrazinamide was tested after administration of each drug in free combinations and in a fixed-dose combination of the three drugs, known as Trifazid.
OBJECTIVE
To examine the relative bioavailability of rifampicin, isoniazid and pyrazinamide after oral administration of the drugs given alone in comparison to that of the same drugs after administration of Trifazid.
DESIGN
An open, randomized, cross-over study comprising 16 healthy volunteers.
RESULTS
The pattern of absorption, plasma concentrations and pharmacokinetic parameters were very similar after administration of the drugs in free and fixed combinations.
CONCLUSION
The triple combination of antituberculosis drugs could replace the separate drugs in the treatment of tuberculosis.
背景
在分别给予利福平、异烟肼和吡嗪酰胺以及给予这三种药物的固定剂量组合（称为三联抗痨片）后，对它们的吸收情况进行了测试。
目的
比较单独口服利福平、异烟肼和吡嗪酰胺与口服三联抗痨片后这三种药物的相对生物利用度。
设计
一项开放性、随机、交叉研究，纳入16名健康志愿者。
结果
分别给予药物和给予固定剂量组合药物后，吸收模式、血浆浓度和药代动力学参数非常相似。
结论
抗结核药物的三联组合可替代单一药物用于结核病治疗。
Zotero 插件